Press Release
16 Sep, 2020
Beijing, Sept. 16, 2020——InnoCare Pharmaceuticals, a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases, announced today that the company will present at the upcoming Morgan Stanley 2020 Virtual Asia Pacific Conference and ZGC Forum.
02 Jul, 2020
InnoCare Pharmaceuticals (HKEX: 09969), after successfully dosing the first patient in a Phase 2 trial of ICP-192 for urothelial cancer, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with cholangiocarcinoma.
28 Jun, 2020
InnoCare Pharmaceuticals (HKEX: 09969), a leader in the fields of cancer and autoimmune diseases, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with urothelial cancer.
01 Jan, 0001
On June 28, 2020, InnoCare (Stock Code:09969-HK), a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Mr. Xiaodong Jin as Chief Commercial Officer (CCO).
24 Apr, 2020
On April 24th of 2019, InnoCare announced the approval of their proprietary pan-FGFR inhibitor ICP-192 by the US Food and Drug Administration (FDA) for initiation of clinical investigations. ICP-192 is the second innovative drug candidate from InnoCare approved for initiation of clinical trials in the US. ICP-192 is a highly selective pan-FGFR inhibitor targeting multiple solid tumors with FGFR gene aberrations. Currently phase I/II studies are underway in China, with encouraging preliminary results on safety and tolerability. Following the IND approval, InnoCare will soon initiate clinical studies in the US for ICP-192. InnoCare will also actively explore collaboration opportunities with innovative biotech and pharmaceutical companies in these areas. “In less than one year, another innovative drug candidate from InnoCare has obtained the FDA approval for initiation of clinical investigation. This further demonstrates the profound innovation capability of InnoCare. We will continuously focus our effort on discovering and developing safe and effective therapies for the benefit of patients around the world. " Said Dr. Jasmine Cui, co-founder, Chairman, and CEO of InnoCare.